Overall, our data underscore the pertinence of HER2+ 3DiBC in recapitulating crucial biological processes associated with BC patient response to treatment and indicate that FAP-IL2v may restore trastuzumab-mediated ADCC against BCCs in unresponsive HER2+ BC. The gene discussed is ERBB2; the disease is breast cancer.